Y. Yan

First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.

C. Jones, J. Baselga, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.

S. Loi, D. Miles, J. Sohn, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.

D. Schadendorf, P. Ascierto, M. Mandalà, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

G. Demetri, J. Ware, P. LoRusso, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study.

K. Flaherty, J. Larkin, H. Gogas, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.

P. Ascierto, L. Demidov, R. Gutzmer, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study

R. Huddart, T. Powles, A. Gramza, 2023, ESMO open.

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

J. Tabernero, N. Segal, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.

J. Ware, Yibing Yan, D. Sarker, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

P. Ascierto, J. Larkin, J. Sosman, 2016 .